Career Enhancement Program
Specific AIMS:
The Career Development Program (CEP) of the Dana-Farber Harvard Cancer Center Kidney Cancer SPORE has been very successful at developing the next generation of translational researchers in kidney cancer over the last 10 years. It will continue to accomplish this goal by:
- Soliciting applications for CEP awards
- Selecting Awardees
- Mentoring the recipients of CEP awards
- Monitoring the progress of CEP awardees careers
- Evaluating the success of the CEP on an ongoing basis
Awarded in 2020
Evaluating Endogenous Retrovirus as Antigenic Targets of CD8+ T Cells in RCC
Investigator: D. Braun (DFCI)
Clinical Characterization of Kidney Injury Molecule-1 (Kim-1) as a Biomarker in Renal Cell Carcinoma
Investigator: W. Xu (BIDMC)
Awarded in 2019
Evaluating Endogenous Retrovirus as Antigenic Targets of CD8+ T Cells in RCC
Investigator: D. Braun (DFCI)
CliniCal Characterization of Kidney Injury Molecule-1 (Kim-1) as a Biomarker in Renal Cell Carcinoma
Investigator: W. Xu (BIDMC)
Awarded in 2018
Is Vista an Actionable lmmune Checkpoint Target in Kidney Cancer?
Investigator: K. Mahoney (BIDMC)
Detecting and Targeting Mitochondrial Vulnerabilities in Kidney Cancer
Investigator: R.Gopal (MGH)
Awarded in 2017
LAT1 and GLS1 Inhibitors for Treatment of Renal Cell Carcinoma
Investigator: D. Christodoulou (MGH)
Vista an Actionable Immune Checkpoint Target in Kidney Cancer
Investigator: K. Mahoney (BIDMC)
Awarded in 2015
Dysregulated Chromatin Modifications Yield Novel Targets in Clear Cell Renal Cell Carcinomas
Investigator: A. Chakraborty (DFCI)
Elucidating Mechanisms Driving Renal Medullary Carcinomas to Deliver a Rational Approach to Cancer Directed Therapy
Investigator: A. Hong (DFCI)
Awarded in 2013
Validation of YAP as a Therapeutic Target in RCC
Investigator: Chungling Yi, PhD (Georgetown)
Awarded in 2012
Optimization of Surveillance Strategies Following Localized Kidney Cancer Therapy
Investigator: Steven Lee Chang, MD (BWH)
Awarded in 2011
Evaulation of CUB-domain-containing protein 1(CDCP1) as a potential biomarker and therapeutic target for renal cell carcinoma (RCC)
Investigator: Brooke Emerling, PhD (BIDMC)
Awarded in 2010
Functional Analysis of the Tumor Suppression Role of HIF1α in Kidney Cancer
Investigator: Chuan Shen, PhD (DFCI)
Awarded in 2009
Exploring FoxO Transcriptional Network in Kidney Cancer
Investigator: Boyi Gan, PhD (DFCI)
Identification of Novel Biomarkers Using Integrative and Systems Biology Oriented Analysis of RCC
Investigator: Manoj Bhasin, PhD (BIDMC)
Awarded in 2008
Small molecule screen uncovers IRP1-mediated HIF translational repression
Investigator: Michael Zimmer, MD (MGH)
Evaluation of phosphoinositide 3-kinase (PI3K) and CXCR4 activation in renal cell carcinoma
Investigator: Kevin Courtney, MD, PhD (DFCI)
The balance of angiogenesis and angiostasis determines response and resistance to antiangiogenic therapies
Investigator: Rupal Bhatt, MD (BIDMC)
Awarded in 2006
Enhancing the efficacy of Sorafenib and Sunitinib in the treatment of advanced RCC by concurrent inhibition of additional kinases
Investigator: Cho, Daniel, MD (BIDMC)
The Biochemical basis of the differential risk of RCC associated with Type 2A and Type 2B von Hippel-Lindau disease
Investigator: Lianjie Li, PhD (DFCI)
Awarded in 2005
Human Kidney Injury Molecule-1 (hKIM-1) in Renal Cell Carcinoma
Investigator: Won K Han. MD (BWH)
Evaluation of the Response and Resistance of Clear Cell Kidney Cancer to VEGF-Ative Agents with Monocrystalline Iron Oxide Nanoparticle (MION)-Enhanced MRI
Investigator: Robert Ross, MD (MGH)
Awarded in 2003
Determining the Role of HIF1 and HIF2 in VHL Associated Tumorigenesis
Investigator: William Y. Kim, MD (DFCI)
Gene Profiling of Renal Cancer Cell Endothelium
Investigator: Pankaj Seth, PhD (BIDMC)